Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS

NCT01668654 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
4
Enrollment
INDUSTRY
Sponsor class

Stopped FDA placed a clinical hold on the Pediatric Program requiring retigabine discontinuation in subjects; early termination allows for timely reporting of results.

Conditions

Interventions

Sponsor

GlaxoSmithKline

Collaborators